Infections caused by non–carbapenemase-producing carbapenem-resistant Enterobacteriaceae present challenges in the treatment paradigm. Given the limited clinical data, the preferred therapeutic approach remains unknown.
BEJOY PAUL MANIARA, PHARMD, BCPS, BCIDP
Advertisement
Articles by BEJOY PAUL MANIARA, PHARMD, BCPS, BCIDP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
FDA Approves Ensitrelvir as First Oral Post-Exposure Prevention Option for COVID-19
2
Migration Trends Demonstrate Rare, But Increasing Malaria Cases in New York City
3
Post-Exposure Protocol for STDs Prompts Resistant Gonorrhea
4
PolyPid Completes FDA NDA Submission for D-PLEX100 in Surgical Site Infection Prevention
5